Global Market Study on Migraine Drugs Market (2016 to 2026) - CAGR Expected to Grow at 17.2% from 2018 to 2026 -

DUBLIN--()--The "Global Migraine Drugs Market Analysis 2019" report has been added to's offering.

The Global Migraine Drugs market is expected to reach $6.94 billion by 2026 growing at a CAGR of 17.2% from 2018 to 2026.

Key Questions Answered in this Report:

  • How this market evolved since the year 2016
  • Market size estimations, forecasts and CAGR for all the segments presented in the scope
  • Key Market Developments and financials of the key players
  • Opportunity Analysis for the new entrants
  • SWOT Analysis of the key players
  • Fastest growing markets analysed during the forecast period

Migraine drugs are utilized in the treatment of headaches related with migraine. Factors for example, rise in female population and surge in awareness among patients related to prevention and treatment are driving the market growth. Though, side effects associated with these drugs are projected to inhibit the growth of the market.

By drug type, abortive medicines segment acquired significant growth in the market as they can be taken by self-injection, mouth, skin patch, or nasal spray. These forms of medication are especially useful for people who have nausea or vomiting related to their migraine, and they work quickly.

The key vendors mentioned are Abbott, Allergan, AstraZeneca, Bayer, Eli Lilly, Endo International, Ethypharm, GlaxoSmithKline, Impax, Johnson and Johnson, Kowa Pharmaceuticals America, Merck, Pfizer, Teva and Winston Pharmaceuticals.

Key Topics Covered:

1 Market Synopsis

2 Research Outline

2.1 Research Snapshot

2.2 Research Methodology

2.3 Research Sources

2.3.1 Primary Research Sources

2.3.2 Secondary Research Sources

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Migraine Drugs Market, By Type

5.1 Introduction

5.2 Abortive Medicines

5.3 Preventive medicines

5.4 Rizatriptan

5.5 Sumatriptan

5.6 Zolmitriptan

5.7 Ergot Alkaloids

5.8 Other Drug Types

6 Global Migraine Drugs Market, By Drug Class

6.1 Introduction

6.2 Calcitonin Gene-Related Peptide (CGRP)

6.3 Acetylcholine Inhibitors/ Neurotoxins

7 Global Migraine Drugs Market, By Product

7.1 Introduction

7.2 Therapeutic Class

7.3 Treatment Class

8 Global Migraine Drugs Market, By Route of Administration

8.1 Introduction

8.2 Injection

8.3 Oral

8.4 Other Route of Administrations

9 Global Migraine Drugs Market, By Application

9.1 Introduction

9.2 Clinics

9.3 Hospitals

9.4 Household Use

9.5 Other Applications

10 Global Migraine Drugs Market, By End User

10.1 Introduction

10.2 Retail Pharmacies

10.3 Online Pharmacies

10.4 Hospitals Based Pharmacies

11 Global Migraine Drugs Market, By Geography

11.1 Introduction

11.2 North America

11.3 Europe

11.4 Asia Pacific

11.5 South America

11.6 Middle East & Africa

12 Strategic Benchmarking

13 Vendors Landscape

13.1 Abbott

13.2 Allergan

13.3 AstraZeneca

13.4 Bayer

13.5 Eli Lilly

13.6 Endo International

13.7 Ethypharm

13.8 GlaxoSmithKline

13.9 Impax

13.10 Johnson and Johnson

13.11 Kowa Pharmaceuticals America

13.12 Merck

13.13 Pfizer

13.14 Teva

13.15 Winston Pharmaceuticals

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900